Harrow announces Amir Shojaei, PharmD, PhD joins as CSO

Harrow (HROW) announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer CSO. With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. Prior to that, he held senior executive roles at leading pharmaceutical companies, including CEO of TherOptix Corporation, where he advanced a novel drug-eluting contact lens platform, and in various leadership roles at Novartis Pharmaceuticals and Shire PharmaceuticalsDr. Shojaei succeeds Dennis E. Saadeh, PharmD, who is retiring after nearly a decade of service to Harrow, including his most recent role as CSO. …